Sk Chemicals Co., Ltd.

J2h Biotech Inc.

Tiumbio Co., Ltd.

Oncobix Co., Ltd.

In2gen Co., Ltd.

Agathonbio Co., Ltd.

Jae-Sun Kim

Bong-Yong Lee

Nam Kyu Lee

Ju Young Lee

Je Ho Ryu

Keun-Ho Ryu

Jung-Hoon Oh

Nam Ho Kim

Jee-Woong Lim

Jin Young Choi

Hun-Taek Kim

Sooheun Lee

Soo-Min Lee

Ye-Ji Jeon

Jaeseung Ahn

Jin Young Lee

Dae-Kee Kim

Yeo-Jin Park

Hyung-chul Ryu

Guang-Jin Im

Key An Um

Tae Kon Kim

Joon-Gyo Oh

Won-Jae Choi

Sang-hwan Kang

Min-Young Han

Hyung-Chul Ryu

Wenling Song

Jeong A Lee

Yong-Hyuk Kim

Woo Jae Jang

Euisun Park

Suk Ho Lee

Taekyung Yoo

Dong-Gyu Kim

Hyun Jung Lee

So-young Lee

Sunho Lee

Sung-Eun Kim

Hyun-Jung Lee

Ju-Young Lee

Dong Chul Shin

Sung-hoon Park

Seon-Mi Kim

Jung-Woo Seo

Jung A Lee

Jung Bum Yi

Jae Cheol Lee

Won-No Youn

Young-Ah Shin

Yoon-Jung Lee

Yong Youn Hwang

Jong-Seob Im

Yong-Youn Hwang

Minhee Lee

Young Ah Shin

Rengasamy Rajesh

Do Seung Kum

Dong-Chul Shin

Joon Ho Sa

Jeongmin Seo

Nam-Ho Kim

Jin-Young Choi

Won-Son Choi

Hoon Cha

Jin Kyung Rho

Eun-Bi Kang

Hyuk-Min Kim

Hyunjun Yang

Dukho Chang

Byung Hwan Ryoo

Yong-Ho Oh

Dae Ho Kang

JongSeob Im

Tae-Gon Kim

Joon Gyo Oh

Do Hyun Ryu

Hyung Chui Ryu

Hoechul Jung

Yeon-Woo Son

Jung-Gun Joung

Hyung-Jun Kim

Sangryul Lee

Woong Sik Kim

Jin-Heung Sung

Hoe-chul Jung

Key-An Um

Sun-Joo Kim

Hae-In Rhee

Junwon Lee

Kyong Cheol Kim

Young-Jue Bang

Jeong-soo Jang

The present invention provides: novel compounds capable of producing monomethyl fumarate after the compounds are administered; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treating or alleviating various diseases including immune system abnormalities, neurodegeneration, and/or inflammatory diseases.

Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof

The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis.

Pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis

The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.

Compounds useful for treatment or prevention of muscular dystrophy and derivatives for treatment, amelioration or prevention of muscular dystrophy in medicinal use thereof

The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.

Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease

A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.

Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same

The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereof. The compound effectively controls GPR40, and thus, can be effectively used for the prophylaxis or treatment of diseases associated with GPR40, for example, diabetes and many other diseases.

Tricyclic compound and use thereof

The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.

Patch containing rivastigmine

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Disclosed is a composition effective in reducing skin wrinkles. The composition comprises a phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Composition for reducing skin wrinkles including PDE5 inhibitor

Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Composition with improved skin penetration for transdermal delivery of tolterodine

The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same.

Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same

2-pyridyl substituted imidazoles of the formula (I) as shown in claim, are provided, which are useful in the treatment of diseases mediated by ALK5 or ALK4 inhibitors or both.

Growing community of inventors

Suwon-si, South Korea

Jae-Sun Kim